title: Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi's sarcoma: a multicenter study.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Di Lorenzo
authors.forename: Alexander
authors.initials: A
authors.lastname: Kreuter
authors.forename: Rossella
authors.initials: R
authors.lastname: Di Trolio
authors.forename: Attilio
authors.initials: A
authors.lastname: Guarini
authors.forename: Carmela
authors.initials: C
authors.lastname: Romano
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Montesarchio
authors.forename: Norbert H
authors.initials: NH
authors.lastname: Brockmeyer
authors.forename: Sabino
authors.initials: S
authors.lastname: De Placido
authors.forename: Mark
authors.initials: M
authors.lastname: Bower
authors.forename: Bruce J
authors.initials: BJ
authors.lastname: Dezube
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018450:Disease Progression; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000627:therapeutic use / Q000633:toxicity; D005260:Female; D006801:Humans; D008297:Male; D008495:Medical Oncology / Q000379:methods; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use* / Q000633:toxicity; D012189:Retrospective Studies; D012514:Sarcoma, Kaposi / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; D004317:Doxorubicin